Quantitative MYD88L265P and CXCR4S338X analysis to assess clinical trial performance in Waldenstrom macroglobulinemia
Open Access
- 12 March 2026
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (6) , 1954-1958
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Ibrutinib in Previously Treated Waldenström’s MacroglobulinemiaNew England Journal of Medicine, 2015
- Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemiaBlood, 2014
- Constitutive activation of STAT5A and STAT5B regulates IgM secretion in Waldenström's macroglobulinemiaBlood, 2014
- Detection of MYD88 L265P in peripheral blood of patients with Waldenström’s Macroglobulinemia and IgM monoclonal gammopathy of undetermined significanceLeukemia, 2014
- MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reactionBlood, 2013
- Response assessment in Waldenström macroglobulinaemia: update from the VIth International WorkshopBritish Journal of Haematology, 2012
- Lenalidomide and Rituximab in Waldenstrom's MacroglobulinemiaClinical Cancer Research, 2008
- Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248Clinical Cancer Research, 2007
- Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemiaAnnals of Oncology, 2004
- Treatment of Waldenström’s Macroglobulinemia With RituximabJournal of Clinical Oncology, 2002